Acadia Healthcare Company Inc (NASDAQ:ACHC) Director Reeve B. Waud sold 41,865 shares of Acadia Healthcare stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $45.00, for a total value of $1,883,925.00. Following the completion of the transaction, the director now directly owns 14,213 shares in the company, valued at $639,585. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of ACHC remained flat at $$44.75 during mid-day trading on Friday. The stock had a trading volume of 2,255,728 shares, compared to its average volume of 3,271,933. The company has a quick ratio of 1.24, a current ratio of 1.24 and a debt-to-equity ratio of 1.20. Acadia Healthcare Company Inc has a 52-week low of $26.92 and a 52-week high of $45.35. The stock has a market capitalization of $3.66 billion, a PE ratio of 19.46, a PEG ratio of 1.49 and a beta of 0.22.
Several institutional investors and hedge funds have recently bought and sold shares of ACHC. Alpine Woods Capital Investors LLC purchased a new position in shares of Acadia Healthcare during the second quarter valued at approximately $153,000. New Jersey Better Educational Savings Trust purchased a new position in shares of Acadia Healthcare during the second quarter valued at approximately $205,000. Cubist Systematic Strategies LLC purchased a new position in shares of Acadia Healthcare during the first quarter valued at approximately $255,000. Bbva Compass Bancshares Inc. purchased a new position in shares of Acadia Healthcare during the second quarter valued at approximately $259,000. Finally, Strs Ohio purchased a new position in shares of Acadia Healthcare during the third quarter valued at approximately $308,000.
ACHC has been the topic of a number of analyst reports. Zacks Investment Research raised Acadia Healthcare from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research note on Tuesday, July 24th. BidaskClub raised Acadia Healthcare from a “hold” rating to a “buy” rating in a research note on Thursday, September 6th. Jefferies Financial Group lifted their price target on Acadia Healthcare from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, July 31st. Mizuho set a $37.00 price target on Acadia Healthcare and gave the stock a “hold” rating in a research note on Tuesday, August 28th. Finally, Craig Hallum cut Acadia Healthcare from a “buy” rating to a “hold” rating in a research note on Wednesday, October 17th. They noted that the move was a valuation call. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Acadia Healthcare has an average rating of “Hold” and a consensus target price of $43.11.
About Acadia Healthcare
Acadia Healthcare Company, Inc develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities. The company operates acute inpatient psychiatric facilities, which offer evaluation and crisis stabilization of patients with severe psychiatric diagnoses; specialty treatment facilities, including residential recovery facilities, eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders; and residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs.
Further Reading: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.